Evidence map›Paper›PMID 31717887›Full record

ReviewCells2019

Conditional Reprogramming for Patient-Derived Cancer Models and Next-Generation Living Biobanks.

Nancy Palechor-Ceron, Ewa Krawczyk, Aleksandra Dakic, Vera Simic, Hang Yuan, Jan Blancato, Weisheng Wang, Fleesie Hubbard, Yun-Ling Zheng, Hancai Dan and 12 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 83 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 1 country.

Nancy Palechor-CeronDepartment of Pathology, Center for Cell Reprogramming, Georgetown University Medical Center, Washington, DC 20057, USA.
Ewa KrawczykDepartment of Pathology, Center for Cell Reprogramming, Georgetown University Medical Center, Washington, DC 20057, USA.
Aleksandra DakicDepartment of Pathology, Center for Cell Reprogramming, Georgetown University Medical Center, Washington, DC 20057, USA.
Vera SimicDepartment of Pathology, Center for Cell Reprogramming, Georgetown University Medical Center, Washington, DC 20057, USA.
Hang YuanDepartment of Pathology, Center for Cell Reprogramming, Georgetown University Medical Center, Washington, DC 20057, USA.
Jan BlancatoDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA.
Weisheng WangDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA.
Fleesie HubbardDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Maryland, Baltimore, MD 21201, USA.
Yun-Ling ZhengDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA.
Hancai DanDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Maryland, Baltimore, MD 21201, USA.
Scott StromeDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Maryland, Baltimore, MD 21201, USA.
Kevin CullenDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Maryland, Baltimore, MD 21201, USA.
Bruce DavidsonDepartment of Otorhinolaryngology-Head and Neck Surgery, Georgetown University Medical Center, Washington, DC 20057, USA.
John F DeekenInova Translational Medicine Institute, Inova Health System, Fairfax, VA 22031, USA.
Sujata ChoudhuryDepartment of Pathology, Center for Cell Reprogramming, Georgetown University Medical Center, Washington, DC 20057, USA.
Peter H AhnDepartment of Radiation Medicine, Georgetown University Medical Center, Washington, DC 20057, USA.
Seema AgarwalDepartment of Pathology, Center for Cell Reprogramming, Georgetown University Medical Center, Washington, DC 20057, USA.
Xuexun ZhouiCryobiol and iFuture Technologies, Shanghai 200127, China.
Richard SchlegelDepartment of Pathology, Center for Cell Reprogramming, Georgetown University Medical Center, Washington, DC 20057, USA.
Priscilla A FurthDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA.
Chong-Xian PanUniversity of California at Davis, Sacramento, CA 95817, USA.
Xuefeng LiuDepartment of Pathology, Center for Cell Reprogramming, Georgetown University Medical Center, Washington, DC 20057, USA.
Georgetown University · USUniversity of Maryland, Baltimore · USInova Health System · USUniversity of California, Davis · US

Funding

Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI STEPHEN W BYERS · 1990 to 2026
$71.5M
Conditionally Reprogrammed Cell Model for Castration-Resistant Prostate Cancer (CRPC)R01CA222148 · NCI · OHIO STATE UNIVERSITY · PI LIU, XUEFENG · 2019 to 2022
$1.9M
Conditionally reprogrammed cells as a novel tool for biobankingR33CA177466 · NCI · GEORGETOWN UNIVERSITY · PI SCHLEGEL, RICHARD, WELLSTEIN, ANTON · 2013 to 2015
$1.2M
Mechanisms Regulating Reversal of Premalignancy and Threapuetic SensitivityR56DE023259 · NIDCR · GEORGETOWN UNIVERSITY · PI FURTH, PRISCILLA A. · 2012 to 2012
$194k
NCI NIH HHS P30 CA051008NCI NIH HHS R01 CA222148NCI NIH HHS R33 CA177466NIDCR NIH HHS R56 DE023259
6 · The paper itself

Abstract

Traditional cancer models including cell lines and animal models have limited applications in both basic and clinical cancer research. Genomics-based precision oncology only help 2-20% patients with solid cancer. Functional diagnostics and patient-derived cancer models are needed for precision cancer biology. In this review, we will summarize applications of conditional cell reprogramming (CR) in cancer research and next generation living biobanks (NGLB). Together with organoids, CR has been cited in two NCI (National Cancer Institute, USA) programs (PDMR: patient-derived cancer model repository; HCMI: human cancer model initiatives. HCMI will be distributed through ATCC). Briefly, the CR method is a simple co-culture technology with a Rho kinase inhibitor, Y-27632, in combination with fibroblast feeder cells, which allows us to rapidly expand both normal and malignant epithelial cells from diverse anatomic sites and mammalian species and does not require transfection with exogenous viral or cellular genes. Establishment of CR cells from both normal and tumor tissue is highly efficient. The robust nature of the technique is exemplified by the ability to produce 2 × 10

Indexed as

AmidesAnimalsBiological Specimen BanksBiopsyCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCell Culture TechniquesCell DifferentiationCell LineCell Line, TumorCellular ReprogrammingCellular Reprogramming TechniquesCoculture TechniquesEpithelial CellsHumansLung NeoplasmsAmidesPyridinesY 27632conditionally reprogrammed cellsliving biobanksorganoidspatient-derived cancer models

Identifiers

PMID31717887
PMCPMC6912808
OpenAlexW2981934952

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.